Brian Johnson, MD
Ophthalmology · Easley, SCNPI 1588872410
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,503 of the $10,642 with a category attached, or 79.9%. 27 manufacturers reported payments, led by Alcon at 41.2% of the total. Reporting peaked in 2019 at $3,511 and has fallen 56.3% since, to $1,533 in 2025.
Across 281 payments — averaging $37.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$4K
- Johnson & Johnson Surgical Vision, Inc.$2K
- AbbVie$742
- Bausch & Lomb, A Division Of Bausch Health US, LLC$452
- Bausch & Lomb Americas Inc.$346
- Rayner Intraocular Lenses Limited$286
- plus $2K from 21 others
What the payments were for
- Consulting fees$2,13220%
- Food & beverage$8,50380%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 110 | $4,384 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $2,307 |
| AbbVie(2 entities) | 41 | $742 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 34 | $452 |
| Bausch & Lomb Americas Inc. | 13 | $346 |
| Rayner Intraocular Lenses Limited | 10 | $286 |
| Sight Sciences, Inc. | 7 | $272 |
| Rxsight Inc | 3 | $270 |
| Oyster Point Pharma, Inc. | 11 | $237 |
| Glaukos Corporation | 3 | $218 |
| Ocular Therapeutix, Inc. | 9 | $168 |
| Novartis | 10 | $162 |
| Ivantis, Inc | 1 | $161 |
| Tarsus Pharmaceuticals, Inc. | 4 | $117 |
| Mallinckrodt Hospital Products Inc. | 1 | $103 |
| Sun Pharmaceutical Industries Inc. | 4 | $95 |
| Biotissue Holdings Inc. | 3 | $60 |
| Shire North American Group Inc | 3 | $41 |
| Carl Zeiss Meditec USA, Inc. | 1 | $39 |
| Harrow Eye, LLC | 2 | $36 |
| Orthofix Medical, Inc. | 1 | $29 |
| Thea Pharma Inc. | 1 | $25 |
| Dompe US, Inc. | 1 | $21 |
| Omeros Corporation | 1 | $20 |
| Eyepoint US, Inc. | 1 | $18 |
| Amgen | 1 | $18 |
| Boston Scientific | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis Symfony IOL$2,132
- Clareon$401
- RXSIGHT CONTACT LENS$253
- RXSIGHT INJECTOR CARTRIDGE$253
- RXSIGHT INJECTOR HANDPIECE$253
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$253
- LIGHT ADJUSTABLE LENS (LAL)$253
- ReSTOR$251
- AcrySof$248
- AcrySof IQ PanOptix UV IOL$230
- OMNI(R) SURGICAL SYSTEM (US)$189
- Hydrus Microstent$161
- Centurion$152
- Unity$148
- AcrySof IQ PanOptix$142
- ORA$136
- Tecnis IOL$124
- RayOne EMV$124
- RayOne Spheric$124
- RayOne Aspheric$124
How this compares
$10,642 in reported general payments places this provider in the 85th percentile of 293 ophthalmology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 53 | $67,144 |
| LumiganBimatoprost | 71 | $35,027 |
| MieboPerfluorohexyloctane/Pf | 15 | $13,264 |
| Cyclosporine | 18 | $8,870 |
| VyzultaLatanoprostene Bunod | 18 | $4,476 |
| Latanoprost | 437 | $4,375 |
| Travoprost | 23 | $4,203 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $3,387 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 19 | $3,329 |
| Prednisolone Acetate | 69 | $2,379 |
| Timolol Maleate | 165 | $1,233 |
| Doxycycline Hyclate | 35 | $867 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 60 | $618 |
| ValacyclovirValacyclovir Hcl | 18 | $542 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 57 | $537 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $742 | $105,558140 claims |
| Bausch & Lomb Americas Inc.Miebo, Vyzulta | $346 | $17,74033 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 293 ophthalmology providers in South Carolina.
Other ophthalmology in Easley
- Kerry SolomonMt Pleasant$1.7M
- William ClarkWest Columbia$768K
- George WaringMt Pleasant$645K
- Karolinne RochaCharleston$552K
- Joseph BishopHilton Head Island$136K
- Erik HappMt Pleasant$124K
- Matthew ClaryColumbia$119K
- Kunal KanitkarLexington$83K
- Carl SloanMyrtle Beach$78K
- David VromanLadson$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.